We have observed that MEDI9197 can enhance human NK cell killing of target cells (Fig. 1) and can induce NK cell activation in vivo (Additional file 1: Figure S6A), whereas Singh et al. [23] have previously demonstrated that MEDI9197 anti-tumor activity is dependent on CD8+ T cells, but not NK cells, using depletion studies in the B16-OVA model, suggesting NK cells may be involved but are not required for the anti-tumor activity observed in the B16-OVA model, so we focused on further evaluation of the functional status of TILs. This evidence concerns the gene CD8A and neoplasm.